These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
656 related articles for article (PubMed ID: 23862773)
1. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773 [No Abstract] [Full Text] [Related]
2. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038 [TBL] [Abstract][Full Text] [Related]
3. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. Al-Samkari H; Kuter DJ Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577 [No Abstract] [Full Text] [Related]
4. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP]. Mori M; Kato M; Koh K; Hanada R Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675 [TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres. Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125 [TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388 [TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660 [TBL] [Abstract][Full Text] [Related]
8. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876 [TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925 [TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. Atkinson K Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797 [TBL] [Abstract][Full Text] [Related]
11. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim. Piccin A; Amaddii G; Natolino F; Billio A; Cortelazzo S Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912 [No Abstract] [Full Text] [Related]
12. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim]. Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804 [No Abstract] [Full Text] [Related]
14. Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim. Nakazato T; Ito C; Mihara A; Aisa Y Int J Hematol; 2013 Feb; 97(2):291-3. PubMed ID: 23275229 [No Abstract] [Full Text] [Related]
15. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus. Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983 [No Abstract] [Full Text] [Related]
16. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics. Meyer O; Salama A Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379 [TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review. Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713 [TBL] [Abstract][Full Text] [Related]
18. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center. González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127 [No Abstract] [Full Text] [Related]
19. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia. Neunert CE Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404 [TBL] [Abstract][Full Text] [Related]
20. What is publication? The case of eltrombopag. Benham L; Guo L; Turner R Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427 [No Abstract] [Full Text] [Related] [Next] [New Search]